Micromet (MITI) says it entered into a collaboration agreement with Amgen (AMGN) for the...

|By:, SA News Editor

Micromet (MITI) says it entered into a collaboration agreement with Amgen (AMGN) for the research of BiTE antibodies designed to direct the body's cell-destroying T-cells against tumor cells, representing a new therapeutic approach to cancer therapy. MITI +4.5%, AMGN -0.8% premarket. (PR)